Hyaluronic acid and its use as a “rejuvenation” agent in cosmetic dermatology
Author:
- 1 December 2004
- journal article
- review article
- Published by Frontline Medical Communications, Inc. in Seminars in Cutaneous Medicine and Surgery
- Vol. 23 (4) , 218-222
Abstract
Since 1996, hyaluronic acid (HA) has been launched onto the market in Europe. Since then, different companies proposed their HAs. Biomatrix (NJ, USA) proposes an animal-derived HA (from rooster comb). Q-Med AB (Uppsala, Sweden) and LEA-DERM (Paris, France) are the main companies to have a nonanimal HA. HA is produced by bacterial fermentation from a specific strain of streptococci. HA has no species specificity and theoretically has no risk of allergy. No skin testing is necessary before injecting because HA is a biodegradable agent. To be utilized as a filler agent for improving wrinkles, scars, or increasing volumes, HA must be stabilized to obtain a sufficient half-life. Process of stabilization varies, according to each manufacturer. This explains the differences in longevity and in viscosity of the different products. Several HAs are suitable to fine lines, to deep wrinkles/folds, or to increase volume. A new indication for "rejuvenation" is injection into the superficial dermis and epidermis. The HA (stabilized or not) is not used to fill in but rather to hydrate and finally to rejuvenate the skin. This procedure must be repeated at intervals of a few weeks or months. If HA is the safest filler agent in cosmetic indications today, some rare side effects may appear and must be known to inform patients. Most of these complications are not severe and will disappear when the product is degraded.Keywords
This publication has 22 references indexed in Scilit:
- Granulomatous Foreign Body Reaction Against Hyaluronic AcidDermatologic Surgery, 2004
- Evaluation of the safety of a non‐animal stabilized hyaluronic acid (NASHA – Q‐Medical, Sweden) in European countries: a retrospective study from 1997 to 2001Journal of the European Academy of Dermatology and Venereology, 2004
- Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitroBritish Journal of Ophthalmology, 2004
- Effects of Hyaluronic Acid on the Polymorphonuclear Leukocyte (PMN) Release of Active Oxygen and Protection of Bovine Corneal Endothelial Cells from Activated PMNsKorean Journal of Ophthalmology, 2004
- A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Tolerability of Restylane Versus Zyplast for the Correction of Nasolabial FoldsDermatologic Surgery, 2003
- Safety Data of Injectable Nonanimal Stabilized Hyaluronic Acid Gel for Soft Tissue AugmentationDermatologic Surgery, 2002
- Hyaluronic AcidDrugs, 1994
- Abscess formation and local necrosis after treatment with Zyderm or Zyplast Collagen ImplantJournal of the American Academy of Dermatology, 1991
- Zyderm collagen: Implantation technicsJournal of the American Academy of Dermatology, 1984
- Injectable collagen implant—updateJournal of the American Academy of Dermatology, 1983